Abiopharma

Pharmagreen Biotech Inc. (OTC Markets: PHBI) is developing its line of nutraceutical products, a proprietary blend of therapeutic plants and mushrooms. Pharmagreens first new product, MaxGenomic(TM) Supplement, is a proprietary blend, formulated in the U. S. A., of nine medicinal mushrooms and six medicinal plants to help support the human mind and body. This supplement is produced in a U.S.A cGMP facility, in enteric capsules to enhance the bioavailability of the MaxGenomic(TM) supplement. Pharmagreen is also completing its research for its elixir, sublingual version, to provide immediate help and support to those who push their mental and physical capacity to their limits. Utilizing the Companys expertise in plant genetics, tissue culture, Pharmagreens transgenic program uses the current technologies to research and create nutraceutical formulations as daily supplements, with the potential to improve lives and address a wide variety of aliments.

Additional info from OTC:
Pharmagreen Biotech Inc. (OTC Markets: PHBI) is developing its line of nutraceutical products, a proprietary blend of therapeutic plants and mushrooms. Pharmagreens first new product, MaxGenomic(TM) Supplement, is a proprietary blend, formulated in the U. S. A., of nine medicinal mushrooms and six medicinal plants to help support the human mind and body. This supplement is produced in a U.S.A cGMP facility, in enteric capsules to enhance the bioavailability of the MaxGenomic(TM) supplement. Pharmagreen is also completing its research for its elixir, sublingual version, to provide immediate help and support to those who push their mental and physical capacity to their limits. Utilizing the Companys expertise in plant genetics, tissue culture, Pharmagreens transgenic program uses the current technologies to research and create nutraceutical formulations as daily supplements, with the potential to improve lives and address a wide variety of aliments.